"The chelating effect of zinc in patients with Covid 19"

Administration of Zinc-Chelating Agents (intravenuosly CaNa2EDTA) in COVID-19 Patients: A pilot study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210913052453N1

Enrollment

Registered

2021-11-08

Start date

2021-09-23

Completion date

Unknown

Last updated

2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: covid-19. Condition 2: covid-19. Condition 3: covid-19. Condition 4: covid-19. Coronavirus infection, unspecified Dyspnea Cough Pneumonia due to SARS-associated coronavirus

Interventions

Intervention 1: Intervention group: Receiving common drugs for the treatment of Covid-19 in the ICU along with receiving a dose of 50 to 100 mg of calcium EDTA three times a day intramuscularly or int

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with Covid-19 admitted to the Intensive Care Unit (ICU) Patients with Covid-19 with respiratory distress

Exclusion criteria

Exclusion criteria: insulin-dependent diabetic patients Patients with urinary tract disorders Patients with cardiovascular system disorders

Design outcomes

Primary

Measure	Time frame
Blood oxygenation. Timepoint: At the beginning of the study, and 3 days after the study. Method of measurement: Evaluation of blood factors and clinical condition of the patient.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contacthemen moradi-sardareh

Asadabad University of Medical Sciences

hemen.moradi@yahoo.com+98 939 928 3093

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026